Abstract:Background: Prostate cancer (PCa) is the 2nd leading cause of cancer-related death among men in western countries, and a recently developed powerful antiandrogen enzalutamide (Enz) may extend the castration-resistant prostate cancer (CRPC) patients’ survival extra 4.8 months before development of Enz resistance.Methods: Sequencing analysis, Taqman PCR, absolute real time PCR, PDX animal model and Western blotting were used to detect our newly identified androgen receptor (AR) variant (named ARv33 due to having duplicated exon3) in various PC cell lines and human PCa samples. Genomic PCR, minigene were applied to confirm the mechanism of ARv33 generation. The biological functions of ARv33 were examined in both in vitro and in vivo experiments.Findings: ARv33 is generated via a unique trans-splicing mechanism that occurs rarely in human cells. Human clinical sample survey revealed that ARv33 is expressed in the later PCa stage. Mechanism dissection revealed that Enz/AR could function via transcriptional regulating the lncRNA-LINC00312 to promote splicing of the pre-AR transcript to induce the ARv33, which might then alter the B4GALT1 expression to increase the Enz resistance. Results from preclinical studies revealed that ARv33 could complex with ARv7 to increase the Enz resistance in vitro and targeting ARv33 with ARv33-siRNAs suppressed the EnzR tumor growth in an in vivo xenograft mice model. Together.Interpretation: This newly identified ARv33 plays key roles to alter the Enz resistance and targeting this ARv33 may provide us a new and better therapy to further suppress the CRPC that already developed the Enz resistance.Funding Information: This work was supported by George Whipple Professorship Endowment and China National Natural Science Foundation (81903113).Declaration of Interests: All authors declare there is no potential interest related to this manuscriptEthics Approval Statement: The PCa tissue samples used in the study was approved by the ethics committee of University of Rochester Medical Center (URMC). Animal experiments were performed after the approval from the URMC and the University Committee on Animal Resources (UCAR).

The Androgen Receptor Variant ARv33 Increased Enzalutamide-Resistance in Prostate Cancer Via a Unique Trans-Splicing Mechanism

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation

Preclinical Study Using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.

Understanding the development of enzalutamide resistance based on a functional single-cell approach

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer

Natural Killer Cells Suppress Enzalutamide Resistance and Cell Invasion in the Castration Resistant Prostate Cancer Via Targeting the Androgen Receptor Splicing Variant 7 (Arv7)

Androgen-deprivation Therapy with Enzalutamide Enhances Prostate Cancer Metastasis Via Decreasing the EPHB6 Suppressor Expression.

Integrative Transcriptome Analysis Identifies Genes and Pathways Associated with Enzalutamide Resistance of Prostate Cancer

Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7

Linking Prostate Cancer Cell AR Heterogeneity to Distinct Castration and Enzalutamide Responses

Targeting Androgen Receptor (AR) with Antiandrogen Enzalutamide Increases Prostate Cancer Cell Invasion Yet Decreases Bladder Cancer Cell Invasion Via Differentially Altering the AR/circRNA-ARC1/miR-125b-2-3p or Mir-4736/Pparγ/mmp-9 Signals

Targeting the Lnc-OPHN1-5/Androgen Receptor/hnRNPA1 Complex Increases Enzalutamide Sensitivity to Better Suppress Prostate Cancer Progression

Androgen Receptor Splice Variants Activating the Full-Length Receptor in Mediating Resistance to Androgen-Directed Therapy.

Anti‐androgen Enzalutamide Enhances Prostate Cancer Neuroendocrine (NE) Differentiation Via Altering the Infiltrated Mast Cells → Androgen Receptor (AR) → Mirna32 Signals

PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway

TP53 Inhibited AR Signaling Promote Enzalutamide Resistance in LNCaP cell

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

Structural and Molecular Insights into the Mechanism of Resistance to Enzalutamide by the Clinical Mutants in Androgen Receptor (AR) in Castration-Resistant Prostate Cancer (CRPC) Patients